Associazione Nazionale Medici Cardiologi Ospedalieri

CONGRESS ABSTRACT

CONGRESS ABSTRACT

Categorie
Non-response to inclisiran therapy in three patients with statin intolerance: a case series
Anno:
2024
Background: Inclisiran is the first silencing-RNA therapy used to reduce LDL-C. It is also recommended in patients with statin intolerance. We describe a case series of three no-responder patients to inclisiran. Case series: 64-year-old man with medical history of type II diabetes mellitus, obesity, hypertension, chronic kidney disease (eGFR…
CHOLESTEROL-LOWERING THERAPIES IN ACUTE CORONARY SYNDROME: A SINGLE-CENTER OBSERVATIONAL STUDY
Anno:
2024
Background: LDL-cholesterol (LDL-C) is a key target of atherosclerotic cardiovascular disease secondary prevention. We report a cohort study aimed at assessing lipid-lowering drug use in patients hospitalized for acute coronary syndrome (ACS). Methods and results: In this single-center observational study we enrolled 81 patients hospitalized from September to October…